| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | "© 2024 Patient Led Oncology. All rights reserved. This material is provided for personal, non-commercial and informational use only. You may download or print a single copy for your personal reference to use as a base for discussion with your doctor. Unauthorized reproduction, distribution, or use for commercial purposes is strictly prohibited without prior written permission from Patient Led Oncology. For more information, visit Patient Led Oncology. https://www.patientledoncology.com/" | |||||||||||||||||||||||||
2 | ||||||||||||||||||||||||||
3 | The Rainbow Off Label Cancer Protocol OPEN FROM A DESKTOP/TABLET ONLY | |||||||||||||||||||||||||
4 | Download your own copy (will activate selector in protocol builder sheet) | |||||||||||||||||||||||||
5 | ||||||||||||||||||||||||||
6 | Off Label Drugs Protocol Principles | |||||||||||||||||||||||||
7 | This tool was mainly based on more than 4.000 scientific papers on off label drug repurposing for cancer studied and compiled by Jeffrey Dach MD in his book, "Cracking Cancer Toolkit" | |||||||||||||||||||||||||
8 | https://www.amazon.com/Cracking-Cancer-Toolkit-Repurposed-Treatment-ebook/dp/B08PDQV28K | |||||||||||||||||||||||||
9 | Carefully read interactions and interactions for each | |||||||||||||||||||||||||
10 | This workbook is much better read on a desktop | |||||||||||||||||||||||||
11 | There are 7 main pillars to target in order to fight cancer well | |||||||||||||||||||||||||
12 | There are also secondary pathways that must not be targeted but can be targeted | |||||||||||||||||||||||||
13 | It is imperative to have a protocol that covers the seven first pillars to achieve "synthetic lethality" on cancer | |||||||||||||||||||||||||
14 | The more pathways are covered, the better | |||||||||||||||||||||||||
15 | Off label protocols tend to have these advantages over chemotherapy: less inflammation, less sides effects, no immuno-depression and targeting cancer stem cells (which don't divide rapidly so usually not targeted by chemotherapy) | |||||||||||||||||||||||||
16 | In the vast majority of cases off label drugs boost conventional chemo, radio and immunotherapies | |||||||||||||||||||||||||
17 | Disclaimer: This guide is for informational purposes only. Do not consider it medical advice. If you find the informations here interesting, please discuss with your doctor before proceeding. | |||||||||||||||||||||||||
18 | ||||||||||||||||||||||||||
19 | Trust the process, not a single active ingredient! | |||||||||||||||||||||||||
20 | Many Cancer Patients Are Intentionally Using Off-Label Drugs and Supplements (2021 update) - Integrative Oncology Essentials - Please READ | |||||||||||||||||||||||||
21 | There is no single recipe that works, every person is different | |||||||||||||||||||||||||
22 | Every cancer type has its own pathways so there is no one fit for all combination. The best combination is usually suggested by the current studies on specific cancer types + testing | |||||||||||||||||||||||||
23 | Drugs cocktails are the preferred solution as no single drug can target all the pathways necessary to eradicate cancer | |||||||||||||||||||||||||
24 | Measure cancer markers at the beginning of each cocktail. | |||||||||||||||||||||||||
25 | Measure again after 4 to 6 weeks. | |||||||||||||||||||||||||
26 | If they are down, continue ! If not change the combination of drugs! | |||||||||||||||||||||||||
27 | After few month's cycle some drugs by other having the same functions to avoid resistance | |||||||||||||||||||||||||
28 | We have see the best results when off labels are used in conjunction with low-dose chemotherapy, low dose immunotherapy, insulin potentiated vitamin C IV , hyperthermia and also usin a anti Cancer Stem Cells Protocol | |||||||||||||||||||||||||
29 | ||||||||||||||||||||||||||
30 | The 7 main anti cancer cocktails pillars are: Glycolysis, Oxphos, Autophagy, Immune system, Inflammation, HK2/VDAC and Cancer Stem Cells (CSC) | |||||||||||||||||||||||||
31 | There are other secondary pillars that are not mandatory but can but great to target. Among these, the most important ones are VEGF, cytotoxicity and EGFR | |||||||||||||||||||||||||
32 | The successful elimination of cancer requires an anti-cancer therapy that will affect both differentiated cancer cells and CSCs | |||||||||||||||||||||||||
33 | Roughly 50% of the tumors have a mutated p53 (tumor suppressor) gene. This prompts for more molecules in the protocol having a "p53 independent" action | |||||||||||||||||||||||||
34 | Medical counseling is highly recommended as drugs can have unwanted side effects & interactions | |||||||||||||||||||||||||
35 | Off label cures can be cycled with more aggressive cures as ferroptosis (artemisinin), IV Vitamin C or conventional therapies (radiotherapy, chemotherapy) | |||||||||||||||||||||||||
36 | Off label cures are meant to show first results after 4 to 6 weeks and usually need to be continued at least 6 to 24 months | |||||||||||||||||||||||||
37 | During these protocols, it is recommended to support the liver with either TUDCA or Silymarin | |||||||||||||||||||||||||
38 | After successful Cancer targeting (no more visible on PET scan and/or good markers), it is important to continue an ANTI CSC treatment, ideally for one year, to avoid resurgence | |||||||||||||||||||||||||
39 | If there is a recurrence after some time and chemotherapy is restarted, it is important to take chemo sensitization molecules as recurrences are usually less sensitive | |||||||||||||||||||||||||
40 | ||||||||||||||||||||||||||
41 | Cancer Stem Cell Pathways:Wnt/Beta Catenin, Hedgehog, Notch (blocking them all is the most effective CSC strategy) | |||||||||||||||||||||||||
42 | A cancer stem cell protocol is recommended after remission, surgery or chemotherapy | |||||||||||||||||||||||||
43 | See this sheet for more information | |||||||||||||||||||||||||
44 | ||||||||||||||||||||||||||
45 | How to use | |||||||||||||||||||||||||
46 | You need to make your own copy to make the protocol builder work => go to "File" , on the top left of this sheet , and then "make a copy" or "download" (as .xls) | |||||||||||||||||||||||||
47 | Go to protocol builder sheet and choose the molecule you would like to insert in your protocol | |||||||||||||||||||||||||
48 | When you have decided which ingredients to place in your protocol, go to the ingredients list and check the details for each of your ingredients | |||||||||||||||||||||||||
49 | It is very important to check for sides effects and contraindications | |||||||||||||||||||||||||
50 | Medical follow-up (every 2 to 3 months) is recommended since it allows to check if the protocol is working | |||||||||||||||||||||||||
51 | Regularly check (ideally every two weeks): tumor size, tumor markers, hepatic and renal functions, immuno/ blood cells count and nutrients deficiencies | |||||||||||||||||||||||||
52 | Have proper markers at each start, change or end of a protocol: blood cancer markers or scans results | |||||||||||||||||||||||||
53 | After 4 to 6 weeks a protocol must be working , if markers say it does not , do not hesitate to change protocol and/or to target more pathways | |||||||||||||||||||||||||
54 | If using bulk powder, it never hurts to check the purity of ingredients with a portable spectrometer https://linksquare.io/ | |||||||||||||||||||||||||
55 | Go to Drugs.com and add all your meds to check all interactions. There are other tools available as well. https://www.drugs.com/interactions-check.php | |||||||||||||||||||||||||
56 | https://reference.medscape.com/drug-interactionchecker | |||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||
58 | If you wish to learn more about immunotherapy, you can check the companion immunotherapy guide here | |||||||||||||||||||||||||
59 | https://docs.google.com/spreadsheets/d/1oQSkX6Oqk97ldIvthEskofTX9pOL1ythG_7RTTCmIj8/edit?usp=sharing | |||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||
61 | Repurposed Drugs Bibliography | |||||||||||||||||||||||||
62 | https://jeffreydachmd.com/wp-content/uploads/2021/02/Cracking-Cancer-Toolkit-Slides-March-17-2021-V2.0.pdf | |||||||||||||||||||||||||
63 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500791/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500791/ | ||||||||||||||||||||||||
64 | https://www.frontiersin.org/articles/10.3389/fphar.2018.00637/full | “Hard” Drug Repurposing for Precision Oncology: The Missing Link? | ||||||||||||||||||||||||
65 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520519/ | Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy - PMC | ||||||||||||||||||||||||
66 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010222/ | New drugs are not enough-drug repositioning in oncology: An update - PMC | ||||||||||||||||||||||||
67 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521020/ | Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanism of Action Through In Vitro and In Vivo Analyses - PMC | ||||||||||||||||||||||||
68 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269316/ | Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies - PMC | ||||||||||||||||||||||||
69 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394389/ | Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates - PMC | ||||||||||||||||||||||||
70 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864870/ | Drug Repositioning in Glioblastoma: A Pathway Perspective - PMC | ||||||||||||||||||||||||
71 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117216/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117216/ | ||||||||||||||||||||||||
72 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331117/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331117/ | ||||||||||||||||||||||||
73 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528778/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528778/ | ||||||||||||||||||||||||
74 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049054/ | Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin - PMC | ||||||||||||||||||||||||
75 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503803/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503803/ | ||||||||||||||||||||||||
76 | https://pubmed.ncbi.nlm.nih.gov/35301945/ | Drug Repurposing Strategies for Non-cancer to Cancer Therapeutics | ||||||||||||||||||||||||
77 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897051/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897051/ | ||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||
88 | Ferroptosis Biography | |||||||||||||||||||||||||
89 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546896/ | |||||||||||||||||||||||||
90 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481593/ | |||||||||||||||||||||||||
91 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388725/ | |||||||||||||||||||||||||
92 | https://pubmed.ncbi.nlm.nih.gov/33915157/ | |||||||||||||||||||||||||
93 | https://pubmed.ncbi.nlm.nih.gov/31105042/ | |||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||
95 | Cancer Resistance, mutation and drugs cycling | |||||||||||||||||||||||||
96 | https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5703947/ | |||||||||||||||||||||||||
97 | https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3219640/ | |||||||||||||||||||||||||
98 | https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC4693617/ | |||||||||||||||||||||||||
99 | Lessons from applied ecology: cancer control using an evolutionary double bind | |||||||||||||||||||||||||
100 | https://www.nature.com/articles/459508a |